CN102762219A - 口腔护理组合物 - Google Patents
口腔护理组合物 Download PDFInfo
- Publication number
- CN102762219A CN102762219A CN201180010909XA CN201180010909A CN102762219A CN 102762219 A CN102762219 A CN 102762219A CN 201180010909X A CN201180010909X A CN 201180010909XA CN 201180010909 A CN201180010909 A CN 201180010909A CN 102762219 A CN102762219 A CN 102762219A
- Authority
- CN
- China
- Prior art keywords
- magnolol
- oral cavity
- active component
- compositions
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 127
- 239000000284 extract Substances 0.000 claims abstract description 58
- 241000218378 Magnolia Species 0.000 claims abstract description 44
- 238000000034 method Methods 0.000 claims abstract description 25
- VVOAZFWZEDHOOU-UHFFFAOYSA-N magnolol Chemical group OC1=CC=C(CC=C)C=C1C1=CC(CC=C)=CC=C1O VVOAZFWZEDHOOU-UHFFFAOYSA-N 0.000 claims description 128
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 90
- 210000000214 mouth Anatomy 0.000 claims description 80
- BYTORXDZJWWIKR-UHFFFAOYSA-N Hinokiol Natural products CC(C)c1cc2CCC3C(C)(CO)C(O)CCC3(C)c2cc1O BYTORXDZJWWIKR-UHFFFAOYSA-N 0.000 claims description 36
- FVYXIJYOAGAUQK-UHFFFAOYSA-N honokiol Chemical compound C1=C(CC=C)C(O)=CC=C1C1=CC(CC=C)=CC=C1O FVYXIJYOAGAUQK-UHFFFAOYSA-N 0.000 claims description 36
- -1 isopropyl magnolol Chemical compound 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 6
- 208000025157 Oral disease Diseases 0.000 claims description 3
- 208000030194 mouth disease Diseases 0.000 claims description 3
- 230000003203 everyday effect Effects 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 41
- 239000003795 chemical substances by application Substances 0.000 description 29
- 239000000463 material Substances 0.000 description 22
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 238000000605 extraction Methods 0.000 description 17
- 239000000796 flavoring agent Substances 0.000 description 16
- 235000013355 food flavoring agent Nutrition 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 14
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 13
- 239000000600 sorbitol Substances 0.000 description 13
- 206010061218 Inflammation Diseases 0.000 description 12
- 241001362856 Lepisorus miyoshianus Species 0.000 description 12
- 230000004054 inflammatory process Effects 0.000 description 12
- 239000011775 sodium fluoride Substances 0.000 description 11
- 235000013024 sodium fluoride Nutrition 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 10
- 239000004141 Sodium laurylsulphate Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000000080 wetting agent Substances 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- 239000006072 paste Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000007788 liquid Substances 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 238000000227 grinding Methods 0.000 description 7
- 239000004094 surface-active agent Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 239000004408 titanium dioxide Substances 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- QQONPFPTGQHPMA-UHFFFAOYSA-N Propene Chemical group CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000003086 colorant Substances 0.000 description 6
- 239000000551 dentifrice Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 210000003296 saliva Anatomy 0.000 description 6
- 238000000194 supercritical-fluid extraction Methods 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 5
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 5
- 235000010418 carrageenan Nutrition 0.000 description 5
- 229920001525 carrageenan Polymers 0.000 description 5
- 238000005352 clarification Methods 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 239000007937 lozenge Substances 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
- 229940085605 saccharin sodium Drugs 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- 208000006558 Dental Calculus Diseases 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 229940112822 chewing gum Drugs 0.000 description 4
- 235000015218 chewing gum Nutrition 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 229940081974 saccharin Drugs 0.000 description 4
- 235000019204 saccharin Nutrition 0.000 description 4
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 4
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 239000002351 wastewater Substances 0.000 description 4
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241001673966 Magnolia officinalis Species 0.000 description 3
- 241000218377 Magnoliaceae Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 239000001177 diphosphate Substances 0.000 description 3
- 235000011180 diphosphates Nutrition 0.000 description 3
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 208000007565 gingivitis Diseases 0.000 description 3
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- XHXUANMFYXWVNG-ADEWGFFLSA-N (-)-Menthyl acetate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(C)=O XHXUANMFYXWVNG-ADEWGFFLSA-N 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 2
- ZIRURAJAJIQZFG-UHFFFAOYSA-N 1-aminopropane-1-sulfonic acid Chemical compound CCC(N)S(O)(=O)=O ZIRURAJAJIQZFG-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- JJJOZVFVARQUJV-UHFFFAOYSA-N 2-ethylhexylphosphonic acid Chemical compound CCCCC(CC)CP(O)(O)=O JJJOZVFVARQUJV-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 241000605986 Fusobacterium nucleatum Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 239000004384 Neotame Substances 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- 229920000388 Polyphosphate Polymers 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 241000194019 Streptococcus mutans Species 0.000 description 2
- AXMVYSVVTMKQSL-UHFFFAOYSA-N UNPD142122 Natural products OC1=CC=C(C=CC=O)C=C1O AXMVYSVVTMKQSL-UHFFFAOYSA-N 0.000 description 2
- 241001148135 Veillonella parvula Species 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000002272 anti-calculus Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 2
- 229940043256 calcium pyrophosphate Drugs 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000004075 cariostatic agent Substances 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 2
- 229940117916 cinnamic aldehyde Drugs 0.000 description 2
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 235000019800 disodium phosphate Nutrition 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000010642 eucalyptus oil Substances 0.000 description 2
- 229940044949 eucalyptus oil Drugs 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 229960002737 fructose Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
- 229910052753 mercury Inorganic materials 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- 235000019412 neotame Nutrition 0.000 description 2
- HLIAVLHNDJUHFG-HOTGVXAUSA-N neotame Chemical compound CC(C)(C)CCN[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 HLIAVLHNDJUHFG-HOTGVXAUSA-N 0.000 description 2
- 108010070257 neotame Proteins 0.000 description 2
- 231100000344 non-irritating Toxicity 0.000 description 2
- ZVVSSOQAYNYNPP-UHFFFAOYSA-N olaflur Chemical compound F.F.CCCCCCCCCCCCCCCCCCN(CCO)CCCN(CCO)CCO ZVVSSOQAYNYNPP-UHFFFAOYSA-N 0.000 description 2
- 229960001245 olaflur Drugs 0.000 description 2
- 201000001245 periodontitis Diseases 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 238000005498 polishing Methods 0.000 description 2
- 229920000098 polyolefin Polymers 0.000 description 2
- 239000001205 polyphosphate Substances 0.000 description 2
- 235000011176 polyphosphates Nutrition 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229940048084 pyrophosphate Drugs 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 2
- 235000019982 sodium hexametaphosphate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 239000000606 toothpaste Substances 0.000 description 2
- 229940034610 toothpaste Drugs 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 239000001605 (5-methyl-2-propan-2-ylcyclohexyl) acetate Substances 0.000 description 1
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical class CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 1
- MOEFFSWKSMRFRQ-UHFFFAOYSA-N 2-ethoxyphenol Chemical compound CCOC1=CC=CC=C1O MOEFFSWKSMRFRQ-UHFFFAOYSA-N 0.000 description 1
- DDFHBQSCUXNBSA-UHFFFAOYSA-N 5-(5-carboxythiophen-2-yl)thiophene-2-carboxylic acid Chemical compound S1C(C(=O)O)=CC=C1C1=CC=C(C(O)=O)S1 DDFHBQSCUXNBSA-UHFFFAOYSA-N 0.000 description 1
- OZJPLYNZGCXSJM-UHFFFAOYSA-N 5-valerolactone Chemical compound O=C1CCCCO1 OZJPLYNZGCXSJM-UHFFFAOYSA-N 0.000 description 1
- 241000186045 Actinomyces naeslundii Species 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- DHHFDKNIEVKVKS-FMOSSLLZSA-N Betanin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC(C[C@H]2C([O-])=O)=C1[N+]2=C\C=C\1C=C(C(O)=O)N[C@H](C(O)=O)C/1 DHHFDKNIEVKVKS-FMOSSLLZSA-N 0.000 description 1
- DHHFDKNIEVKVKS-MVUYWVKGSA-N Betanin Natural products O=C(O)[C@@H]1NC(C(=O)O)=C/C(=C\C=[N+]/2\[C@@H](C(=O)[O-])Cc3c\2cc(O)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c3)/C1 DHHFDKNIEVKVKS-MVUYWVKGSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- XNRPSTJYNNPDAQ-UHFFFAOYSA-N CC.OC(C(CCCC)P(O)(O)=O)(CC)CC Chemical compound CC.OC(C(CCCC)P(O)(O)=O)(CC)CC XNRPSTJYNNPDAQ-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- 235000007716 Citrus aurantium Nutrition 0.000 description 1
- 240000003791 Citrus myrtifolia Species 0.000 description 1
- 235000000228 Citrus myrtifolia Nutrition 0.000 description 1
- 235000016646 Citrus taiwanica Nutrition 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- XHXUANMFYXWVNG-UHFFFAOYSA-N D-menthyl acetate Natural products CC(C)C1CCC(C)CC1OC(C)=O XHXUANMFYXWVNG-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 229940090898 Desensitizer Drugs 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 229920001908 Hydrogenated starch hydrolysate Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- NGZXDRGWBULKFA-UHFFFAOYSA-N L-Bebeerine Natural products O1C(C(=CC=2CCN3C)OC)=CC=2C3CC(C=C2)=CC=C2OC(C=23)=C(O)C(OC)=CC=2CCN(C)C3CC2=CC=C(O)C1=C2 NGZXDRGWBULKFA-UHFFFAOYSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 244000147568 Laurus nobilis Species 0.000 description 1
- 235000017858 Laurus nobilis Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 240000000783 Origanum majorana Species 0.000 description 1
- 235000006297 Origanum majorana Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 241000605862 Porphyromonas gingivalis Species 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 244000295490 Salvia japonica Species 0.000 description 1
- 235000005794 Salvia japonica Nutrition 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 235000009392 Vitis Nutrition 0.000 description 1
- 241000219095 Vitis Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- UJNOLBSYLSYIBM-WISYIIOYSA-N [(1r,2s,5r)-5-methyl-2-propan-2-ylcyclohexyl] (2r)-2-hydroxypropanoate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)[C@@H](C)O UJNOLBSYLSYIBM-WISYIIOYSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 229940011037 anethole Drugs 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 230000002882 anti-plaque Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000009833 antibody interaction Effects 0.000 description 1
- 230000009831 antigen interaction Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- BBFQZRXNYIEMAW-UHFFFAOYSA-N aristolochic acid I Chemical compound C1=C([N+]([O-])=O)C2=C(C(O)=O)C=C3OCOC3=C2C2=C1C(OC)=CC=C2 BBFQZRXNYIEMAW-UHFFFAOYSA-N 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- UHHXUPJJDHEMGX-UHFFFAOYSA-K azanium;manganese(3+);phosphonato phosphate Chemical compound [NH4+].[Mn+3].[O-]P([O-])(=O)OP([O-])([O-])=O UHHXUPJJDHEMGX-UHFFFAOYSA-K 0.000 description 1
- IRERQBUNZFJFGC-UHFFFAOYSA-L azure blue Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[S-]S[S-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-] IRERQBUNZFJFGC-UHFFFAOYSA-L 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 239000001654 beetroot red Substances 0.000 description 1
- 235000012677 beetroot red Nutrition 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 235000002185 betanin Nutrition 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229940093797 bioflavonoids Drugs 0.000 description 1
- 229940073609 bismuth oxychloride Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- ROPDWRCJTIRLTR-UHFFFAOYSA-L calcium metaphosphate Chemical compound [Ca+2].[O-]P(=O)=O.[O-]P(=O)=O ROPDWRCJTIRLTR-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229940025250 camphora Drugs 0.000 description 1
- 239000010238 camphora Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 238000009500 colour coating Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HASGOCLZFTZSTN-UHFFFAOYSA-N cyclohexane;hexane Chemical compound CCCCCC.C1CCCCC1 HASGOCLZFTZSTN-UHFFFAOYSA-N 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 235000021185 dessert Nutrition 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium;phosphate;dihydrate Chemical group O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- QGGZBXOADPVUPN-UHFFFAOYSA-N dihydrochalcone Chemical compound C=1C=CC=CC=1C(=O)CCC1=CC=CC=C1 QGGZBXOADPVUPN-UHFFFAOYSA-N 0.000 description 1
- PXLWOFBAEVGBOA-UHFFFAOYSA-N dihydrochalcone Natural products OC1C(O)C(O)C(CO)OC1C1=C(O)C=CC(C(=O)CC(O)C=2C=CC(O)=CC=2)=C1O PXLWOFBAEVGBOA-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 231100000317 environmental toxin Toxicity 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- SKSIDEOZXDVBGN-UHFFFAOYSA-N fluoro dihydrogen phosphate Chemical compound OP(O)(=O)OF SKSIDEOZXDVBGN-UHFFFAOYSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000007983 food acid Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 description 1
- TVHALOSDPLTTSR-UHFFFAOYSA-H hexasodium;[oxido-[oxido(phosphonatooxy)phosphoryl]oxyphosphoryl] phosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O TVHALOSDPLTTSR-UHFFFAOYSA-H 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- DCYOBGZUOMKFPA-UHFFFAOYSA-N iron(2+);iron(3+);octadecacyanide Chemical compound [Fe+2].[Fe+2].[Fe+2].[Fe+3].[Fe+3].[Fe+3].[Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] DCYOBGZUOMKFPA-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960001518 levocarnitine Drugs 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229930007503 menthone Natural products 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- BWOROQSFKKODDR-UHFFFAOYSA-N oxobismuth;hydrochloride Chemical compound Cl.[Bi]=O BWOROQSFKKODDR-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 description 1
- 239000010663 parsley oil Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000011049 pearl Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229940045916 polymetaphosphate Drugs 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 229940005657 pyrophosphoric acid Drugs 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- UGTZMIPZNRIWHX-UHFFFAOYSA-K sodium trimetaphosphate Chemical compound [Na+].[Na+].[Na+].[O-]P1(=O)OP([O-])(=O)OP([O-])(=O)O1 UGTZMIPZNRIWHX-UHFFFAOYSA-K 0.000 description 1
- 235000019832 sodium triphosphate Nutrition 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- ANOBYBYXJXCGBS-UHFFFAOYSA-L stannous fluoride Chemical compound F[Sn]F ANOBYBYXJXCGBS-UHFFFAOYSA-L 0.000 description 1
- 229960002799 stannous fluoride Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- JFJZZMVDLULRGK-URLMMPGGSA-O tubocurarine Chemical compound C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CCN3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 JFJZZMVDLULRGK-URLMMPGGSA-O 0.000 description 1
- 229960001844 tubocurarine Drugs 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 239000002888 zwitterionic surfactant Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
- A61K36/575—Magnolia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Birds (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
本文公开了提高木兰提取物中发现的一种或多种活性成分或其合成类似物在口腔组合物中的溶解性和递送的方法。
Description
相关申请的交叉引用
本申请要求2010年2月24日提交的美国临时专利申请号61/307,664的优先权，其通过引用全文并入本文。
背景
在木兰提取物的活性成分(或其合成类似物)和用于配制木兰提取物的传统口腔组合物的递送媒介的组分之间经常有不期望的相互作用，这种相互作用减低这种口腔组合物的有效性能。因此，存在提高木兰提取物的活性成分或它们的合成类似化合物的溶解性和它们与口腔组合物的其它组分之间的积极的相互作用的需要。还存在提高木兰提取物的活性成分或它们的合成类似化合物在口腔组合物中的递送效率的需要，以改进这些活性成分的效率和生物可用性。
概述
本发明的一些实施方案提供提高木兰提取物中发现的活性成分的溶解性的方法，包括将丙二醇和所述活性成分混合。在一些实施方案中，在木兰提取物中发现一种或多种活性成分。在一些实施方案中，在木兰提取物中发现的一种或多种活性成分中的至少一种选自： 木兰酚、和厚朴酚、四氢木兰酚(5,5’-二丙基联苯基-2,2’-二醇)、四氢和厚朴酚(3’,5-二丙基联苯基-2,4’-二醇)、正丁基木兰酚(5,5’-二丁基联苯基-2,2’-二醇)和其两种或更多种的组合。本发明的一些实施方案提供提高木兰提取物中发现的活性成分的合成类似物的溶解性的方法，包括将丙二醇和所述合成类似物混合。在一些实施方案中，所述合成类似物选自异丙基木兰酚、异丁基木兰酚和二氯木兰酚。在一些实施方案中，所述活性成分和丙二醇与口腔可接受的载体混合。
在其它的实施方案中，本发明提供包含在木兰提取物中发现的活性成分或其合成类似物；丙二醇；和口腔可接受的载体的口腔组合物。
进一步的实施方案提供治疗口腔疾病或病症的方法，包括：提供包含以下的组合物：木兰提取物中发现的活性成分或其合成类似物；丙二醇；和口腔可接受的载体；和将该组合物施用到有需要的受试者的口腔。在一些实施方案中，将组合物每天施用到口腔一周时间。在一些实施方案中，将该组合物施用到口腔最多2周。在一些实施方案中，将该组合物施用到口腔持续超过2周时间。
发明详述
本实施方案的方法和组合物通过提供良好增溶、安全和对哺乳动物受试者的细菌感染和/或炎症高度有效的口腔组合物赋予超过现有技术组合物的优点。进一步，本发明的一些实施方案包含木兰提取物的一种或多种活性成分。
本说明书全文所用的表述“载体”或“水性载体”或“口腔可接受的载体”表示任何用于本文的安全和有效的材料。这种材料包括水、溶剂等，其可包含湿润剂例如甘油、山梨醇、木糖醇等。载体或口腔可接受的载体也可包括另外的洁齿剂组分，例如增稠剂、离子活性成分、缓冲剂、防牙垢剂、研磨抛光材料、过氧化物源、碱金属碳酸氢盐、表面活性剂、二氧化钛、着色剂、调味***、甜味剂、抗微生物剂、草本制剂、脱敏剂、减污剂和其混合物。
除非另有说明，本文所用的所有的百分比和比例都是按照口腔护理组合物的重量计。除非另有说明，所有的测量都在25℃进行。
在此说明书和权利要求书全文中，公开某个数值(例如温度、组分的重量百分比等)意指该数值加或减本领域普通技术人员理解的另外的数值，这取决于一般与该数值有关的变量和测量误差度。例如，给定用于测量温度的仪器，本领域普通技术人员理解给定的温度包括最高10％的变化。
本发明的一些实施方案提供了用于提高木兰提取物中发现的一种或多种活性成分或其合成类似物在口腔组合物中的溶解性的方法。在一些实施方案中，该方法包括混合有效量的丙二醇和木兰提取物中发现的一种或多种活性成分或其合成类似物。在一些实施方案中，木兰提取物中发现的一种或多种活性成分的至少一种选自：木兰酚、和厚朴酚、四氢木兰酚、四氢和厚朴酚(3’,5-二丙基联苯基-2,4’-二醇)、5,5'-二正丁基联苯基-2,2'-二醇、正丁基木兰酚(5,5’-二丁基联苯基-2,2'-二醇)。在一些实施方案中，木兰提取物的活性化合物的合成类似物选自：异丙基木兰酚、异丁基木兰酚和二氯木兰酚。在一些实施方案中，口腔可接受的载体不包含丙二醇作为湿润剂。在其它实施方案中，口腔可接受的载体包含丙二醇。
一些实施方案包括通过混合0.05-10%重量的丙二醇和木兰提取物中发现的一种或多种活性成分的至少一种或其合成类似物；和口腔可接受的载体来制备增溶的口腔组合物的方法。在一些实施方案中，丙二醇构成0.1-5%重量的组合物。在其它实施方案中，木兰提取物中发现的一种或多种活性成分的至少一种或其合成类似物存在的量是组合物的0.05-5%重量，优选组合物的0.1-3%重量。
本发明进一步的实施方案提供口腔组合物，其包含(i)有效量的丙二醇；(ii)木兰提取物中发现的一种或多种活性成分中的至少一种或其合成类似物；和(iii)口腔可接受的载体。在一些实施方案中，口腔组合物为口腔护理组合物。
在一些实施方案中，组合物用于抑制口腔组织中的炎症细胞介质在口腔中由感染、环境毒素或创伤引起的炎症位点的过量产生。在一些实施方案中，有效量的木兰提取物中发现的一种或多种活性成分中的至少一种或其合成类似物充分减少促炎症介质的水平或活性，以减少哺乳动物受试者中的浓度到被治疗的受试者口腔组织中的基础水平，而没有不必要地抑制所有胞间介质的活性。
在一些实施方案中，木兰提取物中发现的一种或多种活性成分中的至少一种或其合成类似物的存在量为给予活性物的人或低等动物受试者中具有期望的治疗或预防效果所需，而没有过度的不良副作用(例如毒性、刺激性或过敏反应)，以本发明的方式使用时具有相称的合理的收益/风险比。活性成分的具体的安全和有效量将随以下因素改变，比如：被治疗的具体病症、受试者的健康状况、共同疗法(如有)的特性、所用的具体化合物、具体的剂型、采用的载体和期望的给药方案。本领域技术人员采用本文提供的指引将能够确定用于组合物和方法中的活性成分的安全和有效量。
在高度敏感的组织中，高浓度的木兰可潜在的引起刺激性和加重炎症，而不是减弱它。尽管其它炎症潜在性依赖于个体受试者的体质和对刺激物的反应以及其它和治疗相关的变量，但优选以非刺激性的浓度将木兰提取物中发现的一种或多种活性成分或其合成类似物提供给受试者。“非刺激性”指的是将口腔组合物和哺乳动物受试者的口腔接触不会增加酸痛、疼痛、发红或糙度，也不会使口腔组织的炎症加重或恶化。
此外，木兰提取物中发现的一种或多种活性成分或其合成类似物在口腔组合物中的浓度将依赖递送形式、给药方案、最终益处、病理学和/或对其给药的受试者的个体治疗要求而改变，并且因此预料存在的活性成分的量可改变，如本领域技术人员所认识到的。此外，活性成分的浓度通常依赖于口腔组合物的形式。例如，漱口液通常具有相对低浓度的活性成分，而洁齿剂、凝胶或牙粉根据分散的容易性具有较高的浓度以达到相同的递送剂量。同样，糖果组合物通常具有相对高浓度的活性成分以使当它们溶解或被咀嚼时能充分分散。
本文所用的术语“糖果组合物”包括口香糖和口腔可溶解的片剂、珠和锭剂。唾液溶解锭剂或口香糖产品，且促进和口腔表面的接触延长以便在该产品被使用时，锭剂、片剂、珠或口香糖形式中的活性成分充分递送到目标口腔表面。
本文所指的表述“木兰的提取物”或“木兰提取物”指的是来自木兰科(Magnoliaceae)植物例如凹叶木兰(Magnolia officinalis)(下文称为“木兰”)的干燥的皮层、或树皮的提取物，或这种提取物的合成或半合成等价物或其活性组分。在某些实施方案中，口腔组合物包含从木兰的提取物分离或通过传统合成方法制造的一种或多种活性成分。在其它实施方案中，口腔组合物包含木兰的提取物。优选木兰皮层(凹叶木兰的树皮)的提取物包含以下活性化合物：木兰酚、和厚朴酚、四氢木兰酚(5,5’-二丙基联苯基-2,2’-二醇)和四氢和厚朴酚(3’,5-二丙基联苯基-,2,4’-二醇)，它们已经在体外测试中表明对抗代表性口腔细菌(变异链球菌(S.
mutans)、具核梭杆菌(F. nucleatum)、小韦荣球菌(V. parvula)、内氏放线菌(A. naslundii)、牙龈卟啉单胞菌(P. gingivitis))的杀菌特性。应该注意的是木兰科的任何植物都适用于提取用于本实施方案的活性成分。
在一些实施方案中，提取物包含抗微生物有效浓度的化合物，其选自：木兰酚、和厚朴酚、四氢木兰酚、四氢和厚朴酚(3’,5-二丙基联苯基-,2,4’-二醇)、异丙基木兰酚、异丁基木兰酚和正丁基木兰酚(5,5’-二丁基联苯基-2,2’-二醇)，和其两种或更多种的组合。在其它实施方案中，口腔组合物包含选自以下的一种或多种活性成分：木兰酚、和厚朴酚、四氢木兰酚、四氢和厚朴酚(3’,5-二丙基联苯基-,2,4’-二醇)、正丁基木兰酚(5,5’-二丁基联苯基-2,2’-二醇)和其两种或更多种的组合，其量有效治疗哺乳动物受试者中与细菌和/或炎症相关的口腔病症。
在一些实施方案中，木兰提取物能通过萃取(extraction)的方式制备。在一个萃取方法中，干燥压碎的木兰树皮的粉末形式依序与乙醇、二氯甲烷和环己烷接触以在各步骤形成浓缩的糊剂，最后的糊剂形式溶于约50℃-60℃的加热的石油醚中，然后真空干燥，最终的提取得到包含约5-约10%重量的和厚朴酚和约15-约25%重量的木兰酚的提取物。
在另一个萃取方法中，从干燥的木兰植物树皮制备木兰提取物，且可以通过采用合适的溶剂萃取树皮而制备。优选的溶剂包括甲醇、乙醇、二氯甲烷、己烷 环己烷、戊烷、石油醚、氯仿、盐酸、二氯乙烷和氢化氟代烷，例如1,1,1,2-四氟乙烷或HFA-13A。通常一份植物组织(干基)用5-50份，优选15份-30份的溶剂采用萃取装置萃取，其中溶剂与树皮接触以获得浓缩的糊剂，然后用不同的溶剂对浓缩的糊剂进行一个或多个额外萃取步骤，以在延长的时间(优选约6小时-约1-2天，更优选约1天)进一步浓缩初始得到的糊剂。在一个简化的萃取方法中，干燥压碎的木兰树皮粉末形式和氢化氟代烷(例如1,1,1,2-四氟乙烷(HFA-13A))接触以形成浓缩的最终提取，得到包含5-50%和厚朴酚和5-50%木兰酚的提取物。
在另一个萃取方法中，木兰提取物通过采用二氧化碳(CO2)通过超临界流体萃取(SPE)分离。超临界流体是具有气体和液体的“正常”相之间性质的气体。压力变化控制超临界流体的特性，依据应用，其可从较气体样性能变为较液体样性能。超临界流体采用容易得到的、不贵的和环境安全的溶剂(CO2和H2O)。二氧化碳没有毒性、没有***性、容易得到且容易从萃取的产物中除去。SFE的过程温度通常是低到中。因此，SFE制备几乎不含溶剂的产物，而且进一步避免任何潜在的变质反应。
此外，在其它提取方法学中有可能存在的天然污染物通常不存在于SFE萃取的产物中。例如，化合物例如马兜铃酸(Aristocholic
acid)和生物碱例如木兰箭毒素(magnocurine)和筒箭毒碱被维持在低浓度(例如通常低于0.0002%)。因此，在通过SFE萃取木兰的实施方案中，提取物基本不含通过加热和水带来的化学改变、溶剂残余物和其它人工制品。
本文所用的固体或液体材料的“提取”或“提取”指的是将材料和合适的材料例如溶剂接触以去除期望从材料中提取的物质。这种提取可以通过本领域技术人员已知的传统手段进行，例如通过采用提取装置例如Soxhlet装置，其将固体材料保留在支持容器中，并允许溶剂流过材料；或通过将溶剂和材料混合在一起，然后通过例如过滤或沉降和倾析来分离液体和固体相或两个不混溶的液体相。
在各种提取方法中，本发明的木兰提取物可包含2-95%的木兰酚。在一些实施方案中，木兰酚以5-50%存在于提取物中。在其它实施方案中，木兰酚可以30-50%存在于提取物中。在某些实施方案中，和厚朴酚可以2-95%存在于提取物中。在进一步的实施方案中，和厚朴酚可以5-50%存在于提取物中。在其它实施方案中，和厚朴酚可以30-50%存在于提取物中。
在某些实施方案中，优选木兰提取物的活性成分包含木兰酚、和厚朴酚或两者。木兰酚与和厚朴酚是非离子性的羟基联苯基化合物，其结构表示如下：
。
此外，四氢木兰酚(5,5’-二丙基联苯基-2,2’-二醇)和四氢和厚朴酚(3’,5-二丙基联苯基-2,4’-二醇)分别是木兰酚与和厚朴酚的氢化类似物，它们通常发现于木兰的提取物中，因此可包括在口腔组合物中。此外，5,5’-二丁基联苯基-2,2’-二醇(木兰酚的同系物)也可以包括在口腔组合物中，且该化合物的合成可通过本领域普通技术人员的传统有机合成方法实现。四氢木兰酚(5,5’-二丙基联苯基-2,2’-二醇)、四氢和厚朴酚(3’,5-二丙基联苯基-2,4’-二醇)和5,5’-二正丁基联苯基-2,2’-二醇(木兰酚的同系物)的结构表示如下：
四氢木兰酚
四氢和厚朴酚
5,5’-二正丁基联苯基-2’2-二醇。
用于本发明的口腔可接受的载体包括用于制备牙膏、牙粉、预防性糊剂(prophylaxis pastes)、漱口液、锭剂、口香糖、珠等的传统和已知的载体，且在下文中更完全描述。优选口腔可接受的载体不引起刺激性、肿胀或疼痛，且通常不会产生过敏或不良反应例如胃不适(gastric
upset)、恶心或眩晕。具体载体组分的选择依赖于期望的产品形式，包括洁齿剂、牙膏、牙粉、预防性糊剂、漱口液、锭剂、口香糖、凝胶、涂布剂、糖果剂等。
本发明的术语“漱口液”指的是性质基本上是液体的口腔组合物，例如漱口水、喷雾剂或润洗剂。在这种制剂中口腔可接受的载体通常具有包含水或水和醇混合物的水性相。此外，在多个实施方案中，口腔载体包括下文介绍的湿润剂和表面活性剂。大体上水和醇的重量比的范围为1:1-20:1，优选3:1-10:1，更优选4:1-6:1的量。这种类型的制剂中的水-醇混合物的总量通常占制剂的70-99.9%的量。在多个实施方案中，醇通常是乙醇或异丙醇。
本领域技术人员认识到，本发明的口腔可接受的载体也可包含本领域技术人员已知的各种其它的传统活性成分，包括抗菌斑制剂、增白剂、抗菌剂、牙垢控制(抗牙垢)剂、抗龋剂、敏感剂等。优选载体不会实质性减弱木兰提取物中发现的抗炎症和抗菌活性成分或其合成类似物的有效性。
本发明的口腔组合物的这种液体和其它制剂的pH通常是4.5-10的量。pH可用酸(例如柠檬酸或苯甲酸)或碱(例如氢氧化钠)控制或(用例如柠檬酸钠、苯甲酸盐、碳酸盐或碳酸氢盐、磷酸氢二钠或磷酸二氢钠)缓冲。
在多个实施方案中，含水口腔组合物(例如漱口液)包含湿润剂。该湿润剂通常是湿润剂例如甘油和山梨醇和多元醇例如己二醇或聚乙二醇的混合物，虽然采用聚乙二醇作为湿润剂和另外将它用于提高活性成分的溶解性是任选的。湿润剂的含量通常在5-40%和优选10-30%的范围内。
适合于本发明组合物的表面活性剂包括阴离子、非离子和两性离子表面活性剂。表面活性剂通常存在于本发明的水性口腔组合物中的量是0.01%-5%，优选0.5-2.5%的量。
根据本发明的口腔组合物可任选包括其它材料，例如，清洁剂、调味剂、甜味剂、粘着剂、表面活性剂、泡沫调节剂、研磨剂、pH改性剂、湿润剂、增湿剂、口感剂、着色剂、研磨剂、防腐剂、氟离子源、唾液刺激剂、润肤剂、粘度改性剂、稀释剂、乳化剂、营养素及其组合。可添加到该口腔组合物的各种组分包括，例如，甜味剂例如糖精或糖精钠、醇例如乙醇、氟离子源例如氟化钠、以及甘油、山梨醇、聚乙二醇、Poloxomer聚合物例如POLOXOMER®407、PLURONIC®
F108(二者在BASF公司有售)、烷基多糖苷(APG)、聚山梨醇酯、PEG40、蓖麻油、薄荷醇等。应理解尽管每一个上述分类的材料的一般属性可以不同，但也可有一些共同的属性，而且在两种或更多种这些分类的材料内的任何给定材料可以起到多个目的。优选选择这种载体材料和木兰提取物中发现的活性成分或其合成类似物以及组合物的其它成分相容。
本文中有用的调味剂包括任何可操作用于增强组合物味道的材料或材料的混合物。可采用任何口腔可接受的天然或合成调味剂，例如调味油、调味醛、酯、醇，类似的材料以及它们的组合。调味剂包括香草醛、鼠尾草、马郁兰、欧芹油、留兰香油、肉桂油、冬青油(水杨酸甲酯)、薄荷油、丁香油、桂花油、茴香油、桉树油、柠檬油、水果油和精油，包括衍生自柠檬、橙、酸橙、葡萄柚、杏、香蕉、葡萄、苹果、草莓、樱桃、菠萝等的那些，豆和坚果衍生的调味剂例如咖啡、可可、可乐果、花生、杏仁等，吸附和封装的调味剂和其混合物。提供嘴里的香味和/或其它感觉效果，包括冷或暖效果的成分也包含在本文的调味剂中。这种成分包括薄荷醇、醋酸薄荷酯、乳酸薄荷酯、樟脑、桉树油、桉树脑、茴香脑、丁香酚、肉桂、噁烷酮(oxanone)、[α]-紫罗兰酮、丙烯基邻乙氧基苯酚、麝香草酚、芳樟醇、苯甲醛、肉桂醛、N-乙基-对-薄荷基-3-甲酰胺、N,2,3-三甲基-2-异丙基丁酰胺、3-1-薄荷氧基-1,2-丙二醇、肉桂醛甘油乙缩醛(CGA)、薄荷酮甘油乙缩酮(MGA)和其混合物。一种或多种调味剂任选存在的总量是0.01%-5%，在多个实施方案中任选是0.05-2%、0.1%-2.5%和0.1-0.5%。
本文有用的甜味剂包括葡萄糖、聚葡萄糖、蔗糖、麦芽糖、糊精、干燥转化糖、甘露糖、木糖、核糖、果糖、左旋糖、半乳糖、玉米糖浆、部分水解的淀粉、氢化淀粉水解产物、山梨醇、甘露醇、木糖醇、麦芽糖醇、异麦芽酮糖醇、阿司帕坦、纽甜(neotame)、糖精和其盐、三氯蔗糖、基于二肽的强烈甜味剂、环己氨磺酸盐、二氢查耳酮及其混合物。
口感剂包括在组合物的使用中赋予期望的质感或其它感觉的材料。
本文有用的着色剂包括颜料、染料、色淀和赋予特定光泽或反射性的剂例如珠光剂。在多个实施方案中，着色剂可操作用于在牙表面提供白色或淡色的涂层、用于充当牙齿表面上已被组合物有效接触的位点的指示剂、和/或改变组合物的外观，尤其是颜色和/或不透明度以提高对消费者的吸引力。可用任何口腔可接受的着色剂，包括FD&C染料和颜料、滑石粉、云母、碳酸镁、碳酸钙、硅酸镁、硅酸铝镁、二氧化硅、二氧化钛、氧化锌、红色、黄色、棕色和黑色的氧化铁、亚铁氰化铁铵、锰紫、群青、钛化云母(titaniated
mica)、氯氧化铋和其混合物。一种或多种着色剂任选存在的总量是0.001%-20%，例如0.01%-10%或0.1%-5%。
在一些实施方案中，本发明的口腔组合物可包含任选的作为例如抛光剂有用的研磨剂。可用任何口腔可接受的研磨剂，但是应该选择研磨剂的类型、细度(粒径)和含量以便在组合物的正常使用中牙釉质不会过度磨损。合适的任选的研磨剂包括二氧化硅(例如沉淀二氧化硅或作为和氧化铝混合的形式)、不溶的磷酸盐、碳酸钙和其混合物。作为研磨剂有用的不溶的磷酸盐是正磷酸盐、聚偏磷酸盐和焦磷酸盐。说明性的实例是正磷酸二钙二水合物、焦磷酸钙、焦磷酸钙、磷酸三钙、聚偏磷酸钙和不溶的聚偏磷酸钠。
在一些实施方案中，本发明的组合物任选包含牙垢控制(防牙垢)剂。本文有用的牙垢控制剂包括任何这些剂的盐，例如它们的碱金属和铵盐：磷酸盐和多磷酸盐(例如焦磷酸盐)、聚氨基丙磺酸(AMPS)、聚烯烃磺酸盐、聚烯烃磷酸盐、二膦酸盐例如氮杂环烷-2,2-二膦酸盐(例如氮杂环庚烷-2,2-二膦酸)、N-甲基氮杂环庚烷-2,3-二膦酸、乙烷-1-羟基-1,1-二膦酸(EHDP)和乙烷-1-氨基-1,1-二膦酸盐、膦酰基链烷羧酸。有用的无机磷酸盐和多磷酸盐包括磷酸二氢钠、磷酸氢二钠和磷酸三钠、三聚磷酸钠、四聚磷酸盐、焦磷酸一、二、三和四钠、三偏磷酸钠、六偏磷酸钠和其混合物。
在其它的实施方案中，本发明的口腔组合物任选包含例如作为抗龋剂有用的氟离子源。可用任何口腔可接受的氟离子源，包括氟化钾、氟化钠和氟化铵和单氟磷酸盐、氟化亚锡、氟化铟、氟化胺例如奥拉氟(N'-十八烷基三甲撑二胺-N,N,N'-三(2-乙醇)-二氢氟酸)和其混合物。一种或多种氟离子源任选存在的量为提供临床有效量的可溶氟离子给口腔组合物。
在进一步的实施方案中，本发明的口腔组合物任选包含有用于例如改善口干的唾液刺激剂。可用任何口腔可接受的唾液刺激剂，包括但不限于食品酸例如柠檬酸、乳酸、苹果酸、琥珀酸、抗坏血酸、己二酸、富马酸和酒石酸及其混合物。一种或多种唾液刺激剂任选以唾液刺激有效的总量存在。
在另外的实施方案中，本发明的口腔组合物任选包含营养素。合适的营养素包括维生素、矿物质、氨基酸和其混合物。维生素包括维生素C和D、硫胺素、核黄素、泛酸钙、尼克酸、叶酸、烟酰胺、吡哆醇、氰钴胺素、对氨基苯甲酸、生物类黄酮和其混合物。营养添加物包括氨基酸(例如L-色氨酸、L-赖氨酸、甲硫氨酸、苏氨酸、左卡尼汀和L-肉毒碱)、亲脂剂(例如胆碱、肌醇、甜菜碱和亚油酸)和其混合物。
在一些实施方案中，本发明提供治疗与口腔细菌的存在相关的病症的方法，包括提供根据任何上述实施方案的口腔组合物和将口腔组合物施用给哺乳动物受试者的口腔。在一些实施方案中，该方法包括重复施用组合物数次直到在受试者达到期望的抗菌和/或抗炎效果。
本文所指的口腔组织的“炎症”一般指的是通过组织损伤或破坏引发的局部保护性反应，其作用于破坏、稀释或隔离有害剂和损伤的组织两者。在急性形式，其特征在于疼痛、灼热、发红、肿胀和失去功能。慢性炎症是缓慢的过程，其主要特征在于形成新的***。慢性炎症通常是急性炎症的延续或延长的炎症的低度形式(例如与牙周炎或牙龈炎相关的炎症)，且通常引起永久的组织损害。组织学上，炎症涉及复杂的系列事件，包括伴随提高的渗透性和血流的小动脉、微血管和小静脉的扩张；体液(包括血浆蛋白)渗出和白细胞迁移进入炎症位点。炎症相应于促炎症细胞介质或从细胞中释放的物质的水平升高，例如作为抗原和抗体相互作用或抗原和敏化淋巴细胞的作用的结果。
在多个实施方案中，采用合适的被覆材料(dressing material)通过润洗、涂覆、刷洗或层化来实现施用或接触。在一些实施方案中，接触也包括在食用或咀嚼时的偶然接触。在多个实施方案中，施用组合物包括采用施用装置，其帮助保持包含木兰提取物的抗炎症活性成分对目标组织的足够的接触时间，以便允许药理学抑制一种或多种炎症介质例如PGE2和TNF-α的产生升高。
在某些实施方案中，口腔组合物不是有意吞服，而是在口腔中保留足够的时间以发挥预期效用。在其它实施方案中，特别是其中口腔组合物提供给动物产品例如宠物食品、宠物食品添加物(例如点心)或咀嚼玩具中的实施方案中，口腔组合物可在对动物无害的低浓度摄入。优选用于本发明的具体材料和组合物是药学或美容可接受的。
一些实施方案提供口腔组合物，该组合物包含：约0.05-约10%重量的丙二醇；约0.05-约5%重量的木兰提取物中发现的一种或多种活性成分或其合成类似物；和口腔可接受的载体。
一些实施方案提供其中一种或多种活性成分中的至少一种是四氢木兰酚的组合物。在一些实施方案中，一种或多种活性成分中的至少一种是四氢和厚朴酚。在其它实施方案中，一种或多种活性成分中的至少一种是5,5'-二正丁基-联苯基-2,2'-二醇。
一些实施方案提供治疗口腔疾病或病症的方法，其包括：提供包含以下的组合物：约0.05-约10%重量的丙二醇，约0.05-约5%重量的木兰提取物中发现的一种或多种活性成分或其合成类似物；和口腔可接受的载体；以及将该组合物施用到有需要的受试者的口腔。
在一些实施方案中，口腔的疾病或病症包括牙齿、口腔粘膜、齿龈或舌头的疾病或病症。这种疾病或病症包括龋齿、牙龈炎、牙周炎和美容病症例如发黄和恶臭。
本发明将以具体实施例的方式更详细地描述。下列实施例为了说明的目的而提供，并不旨在以任何方式限制本发明的范围。本领域技术人员容易意识到各种非关键性的参数可以被改变或修改而得到基本上相同的结果。
实施例
具有列于下表中的成分的口腔组合物可通过以下方法制备。将氟化钠和任何其它盐分散在水中。将湿润剂例如甘油和山梨醇在搅动下在传统混合器中加入混合物。搅动得到的混合物直到形成均一的凝胶相。将颜料例如二氧化钛加入凝胶相中，以及所需的任何酸或碱(例如NaOH)将pH调整到6-7。然后加入有机增稠剂、角叉菜胶和CMC。混合这些成分直到获得均一相。然后将混合物转移到高速真空混合器，往其中加入二氧化硅研磨剂和二氧化硅增稠剂。然后在约20-50
mm汞柱优选约30mm汞柱的真空下将混合物高速混合5-30分钟。称重调味油，然后将木兰提取物或它们的活性成分加入调味油中。将调味油和木兰活性物加入混合物中。最后加入表面活性剂例如十二烷基硫酸钠(SLS)。得到的产物是增溶的，稳定的，有效的，均一的，半固体的可挤出的糊剂或凝胶产品。
实施例
1
表1显示一种增溶和有效的口腔组合物，其含有丙二醇和四氢和厚朴酚(木兰提取物中发现的活性成分之一)。
表1。
| 成分 | 量 (%) |
| 净化水 | 29 |
| 山梨醇 | 19.45 |
| 甘油 | 20 |
| CMC钠-12型USP | 1.1 |
| ι角叉菜胶 | 0.4 |
| 糖精钠-USP | 0.3 |
| 氟化钠 | 0.24 |
| Zeodent-115 | 8.5 |
| Zeodent-165 | 3 |
| Sylodent XWA650 | 10 |
| 二氧化钛 | 0.5 |
| 十二烷基硫酸钠粉末-NF | 1.5 |
| 调味剂 | 1 |
| 丙二醇 | 4.5 |
| 四氢和厚朴酚 | 0.5 |
| 总计 | 100 |
实施例
2
表2显示一种增溶和有效的口腔组合物，其含有丙二醇和5,5'-二正丁基-联苯基-2,2'-二醇(木兰酚的结构类似物，木兰提取物中发现的活性成分之一)。
表2。
| 成分 | 量 (%) |
| 净化水 | 29 |
| 山梨醇 | 19.45 |
| 甘油 | 20 |
| CMC钠-12型USP | 1.1 |
| ι角叉菜胶 | 0.4 |
| 糖精钠-USP | 0.3 |
| 氟化钠 | 0.24 |
| Zeodent-115 | 8.5 |
| Zeodent-165 | 3 |
| Sylodent XWA650 | 10 |
| 二氧化钛 | 0.5 |
| 十二烷基硫酸钠粉末-NF | 1.5 |
| 调味剂 | 1 |
| 丙二醇 | 4.5 |
| 5,5'-二正丁基-联苯基-2,2'-二醇 | 0.5 |
| 总计 | 100 |
实施例
3
表3显示一种增溶和有效的口腔组合物，其含有丙二醇和合成和厚朴酚(木兰提取物中发现的活性成分之一)。
表3。
| 成分 | 量 (%) |
| 净化水 | 32.51 |
| 山梨醇 | 19.45 |
| 甘油 | 20 |
| CMC钠-12型USP | 1.1 |
| ι角叉菜胶 | 0.4 |
| 糖精钠-USP | 0.3 |
| 氟化钠 | 0.24 |
| Zeodent-115 | 8.5 |
| Zeodent-165 | 3 |
| Zeodent-105 | 10 |
| 二氧化钛 | 0.5 |
| 十二烷基硫酸钠粉末-NF | 1.5 |
| 调味剂 | 1 |
| 丙二醇 | 1 |
| 合成和厚朴酚 | 0.5 |
| 总计 | 100 |
实施例
4
表4显示一种增溶和有效的口腔组合物，其含有丙二醇和天然和厚朴酚(木兰提取物中发现的活性成分之一)。
表4。
| 成分 | 量 (%) |
| 净化水 | 33.96 |
| 山梨醇 | 20 |
| 甘油 | 20 |
| CMC钠-12型USP | 1.1 |
| ι角叉菜胶 | 0.4 |
| 糖精钠-USP | 0.3 |
| 氟化钠 | 0.24 |
| Zeodent-115 | 7.5 |
| Zeodent-165 | 3 |
| Sylodent XWA 650 | 9 |
| 二氧化钛 | 0.5 |
| 十二烷基硫酸钠粉末-NF | 1.5 |
| 调味剂 | 1 |
| 和厚朴酚 | 0.5 |
| 丙二醇 | 1 |
| 总计 | 100 |
实施例
5
下表5描述的数据表明丙二醇对液体制剂中木兰提取物的溶解性的效果。
表5。
| 成分 | 配方 5A | 配方 5B | 配方 5C | |
| 水 | 41.04 | 40.95 | 40.07 | |
| 山梨醇 | 25.80 | 25.42 | 25.42 | |
| 甘油 | 24.76 | 24.39 | 24.39 | |
| 氟化钠 | 0.30 | 0.29 | 0.29 | |
| 硫酸钠 | 0.62 | 0.61 | 0.61 | |
| Gantrez共聚物 | 2.80 | 2.75 | 2.75 | |
| 氢氧化钠 | 0.75 | 0.74 | 0.74 | |
| 糖精钠 | 0.38 | 0.37 | 0.37 | |
| 十二烷基硫酸钠 | 1.87 | 1.84 | 1.82 | |
| 调味剂 | 1.30 | 1.28 | 1.23 | |
| 木兰提取物(>98%纯度) | 0.39 | 0.38 | 0.37 | |
| 丙二醇 | 0.98 | 1.94 | ||
| 总计 | 100 | 100 | 100 | |
| 制剂外观 | 相分离，奶油状顶层 | 半透明但均一 | 澄清且透明 |
实施例
6
下表6描述的数据表明丙二醇对液体制剂中木兰酚的溶解性的效果。
表6。
| 成分 | 配方 6A | 配方 6B | 配方 6C | |
| 水 | 39.10 | 39.11 | 37.43 | |
| 山梨醇 | 24.04 | 24.04 | 23.73 | |
| 甘油 | 23.07 | 23.07 | 22.77 | |
| 氟化钠 | 0.28 | 0.28 | 0.27 | |
| 硫酸钠 | 0.58 | 0.58 | 0.57 | |
| Gantrez共聚物 | 2.60 | 2.60 | 2.56 | |
| 氢氧化钠 | 0.70 | 0.70 | 0.69 | |
| 糖精钠 | 0.35 | 0.36 | 0.34 | |
| 十二烷基硫酸钠 | 2.21 | 1.72 | 1.7 | |
| 调味剂 | 1.20 | 1.16 | 1.18 | |
| 木兰酚 | 0.59 | 0.59 | 0.58 | |
| 丙二醇 | 5.28 | 5.28 | 8.18 | |
| Tauranol(另外的表面活性剂) | 0.51 | |||
| 总计 | 100 | 100 | 100 | |
| 制剂外观 | 相分离，奶油状顶层 | 相分离，奶油状顶层 | 半透明但均一 |
实施例
7
下表7描述的数据表明丙二醇对液体制剂中丁基木兰酚的溶解性的效果。
表7。
| 成分 | 配方 7A | 配方 7B | 配方 7C | 配方 7D | |
| 水 | 40.86 | 40.23 | 39.49 | 38.00 | |
| 山梨醇 | 25.92 | 25.56 | 25.07 | 24.11 | |
| 甘油 | 24.88 | 24.53 | 24.06 | 23.14 | |
| 氟化钠 | 0.30 | 0.29 | 0.29 | 0.28 | |
| 硫酸钠 | 0.63 | 0.62 | 0.6 | 0.58 | |
| Gantrez共聚物 | 2.80 | 2.76 | 2.71 | 2.61 | |
| 氢氧化钠 | 0.75 | 0.74 | 0.73 | 0.70 | |
| 糖精钠 | 0.37 | 0.37 | 0.36 | 0.35 | |
| 十二烷基硫酸钠 | 1.86 | 1.87 | 1.80 | 1.72 | |
| 调味剂 | 1.26 | 1.21 | 1.18 | 1.15 | |
| 丁基木兰酚 | 0.38 | 0.37 | 0.37 | 0.37 | |
| 丙二醇 | 1.46 | 3.34 | 7.00 | ||
| 总计 | 100 | 100 | 100 | 100 | |
| 制剂外观 | 非常浑浊 | 非常浑浊 | 浑浊 | 澄清且透明 |
实施例
8
下表8描述的数据表明丙二醇对液体制剂中丙基和厚朴酚的溶解性的效果。
表8。
| 成分 | 配方 8A | 配方 8B | 配方 8C | 配方 8D | |
| 水 | 40.86 | 40.26 | 39.46 | 38.00 | |
| 山梨醇 | 25.92 | 25.54 | 25.05 | 24.12 | |
| 甘油 | 24.87 | 24.51 | 24.04 | 23.15 | |
| 氟化钠 | 0.30 | 0.29 | 0.29 | 0.28 | |
| 硫酸钠 | 0.62 | 0.62 | 0.60 | 0.58 | |
| Gantrez共聚物 | 2.80 | 2.76 | 2.71 | 2.61 | |
| 氢氧化钠 | 0.75 | 0.74 | 0.73 | 0.7 | |
| 糖精钠 | 0.37 | 0.36 | 0.36 | 0.35 | |
| 十二烷基硫酸钠 | 1.86 | 1.83 | 1.79 | 1.73 | |
| 调味剂 | 1.27 | 1.26 | 1.24 | 1.16 | |
| 丙基和厚朴酚 | 0.38 | 0.37 | 0.38 | 0.35 | |
| 丙二醇 | 1.46 | 3.35 | 6.97 | ||
| 总计 | 100 | 100 | 100 | 100 | |
| 制剂外观 | 非常浑浊 | 澄清且透明 | 澄清且透明 | 澄清且透明 |
在本专利文件中提及的各个专利、专利申请和印刷出版物都特此通过引用全文并入。
本领域技术人员理解，可对本文描述的实施方案进行许多改变和修改，而不会偏离本发明的精神。旨在所有这种变化都落在请求保护的发明的范围内。
Claims (12)
1. 一种口腔组合物，包括：
约0.05-约10%重量的丙二醇；
约0.05-约5%重量的木兰提取物中发现的至少一种或多种活性成分或其合成类似物，其选自木兰酚、和厚朴酚、四氢木兰酚、四氢和厚朴酚、5,5'-二正丁基-联苯基-2,2'-二醇、异丙基木兰酚、异丁基木兰酚；和
口腔可接受的载体。
2. 权力要求1的组合物，其中丙二醇存在的量为组合物的0.1%-5%重量。
3. 权力要求1或权利要求2的组合物，其中一种或多种活性成分中的至少一种存在的量为组合物的0.1%-3%重量。
4. 任一前述权利要求的组合物，其中一种或多种活性成分中的至少一种是木兰酚。
5. 任一前述权利要求的组合物，其中一种或多种活性成分中的至少一种是和厚朴酚。
6. 任一前述权利要求的组合物，其中一种或多种活性成分中的至少一种是四氢木兰酚。
7. 任一前述权利要求的组合物，其中一种或多种活性成分中的至少一种是四氢和厚朴酚。
8. 任一前述权利要求的组合物，其中一种或多种活性成分中的至少一种是5,5'-二正丁基-联苯基-2,2'-二醇。
9. 任一前述权利要求的组合物，其中一种或多种活性成分中的至少一种是异丙基木兰酚。
10. 任一前述权利要求的组合物，其中一种或多种活性成分中的至少一种是异丁基木兰酚。
11. 一种治疗或预防口腔疾病或病症的方法，包括：
提供包含以下的组合物：
约0.05-约10%重量的丙二醇；
约0.05-约5%重量的木兰提取物中发现的一种或多种活性成分或其合成类似物，其选自木兰酚、和厚朴酚、四氢木兰酚、四氢和厚朴酚、异丙基木兰酚、异丁基木兰酚和5,5'-二正丁基-联苯基-2,2'-二醇；和
口腔可接受的载体；和
施用所述组合物到有需要的受试者的口腔。
12. 权利要求11的方法，其中组合物每天施用至少一周时间。
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30766410P | 2010-02-24 | 2010-02-24 | |
| US61/307664 | 2010-02-24 | ||
| US61/307,664 | 2010-02-24 | ||
| PCT/US2011/026017 WO2011106492A1 (en) | 2010-02-24 | 2011-02-24 | Oral care compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102762219A true CN102762219A (zh) | 2012-10-31 |
| CN102762219B CN102762219B (zh) | 2016-05-04 |
Family
ID=43768879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201180010909.XA Expired - Fee Related CN102762219B (zh) | 2010-02-24 | 2011-02-24 | 口腔护理组合物 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9801940B2 (zh) |
| EP (1) | EP2523676B1 (zh) |
| JP (1) | JP5665888B2 (zh) |
| CN (1) | CN102762219B (zh) |
| AR (1) | AR080294A1 (zh) |
| AU (1) | AU2011220789B2 (zh) |
| BR (1) | BR112012019997A2 (zh) |
| CA (1) | CA2788423A1 (zh) |
| CO (1) | CO6592076A2 (zh) |
| MX (1) | MX2012009139A (zh) |
| RU (2) | RU2552322C2 (zh) |
| SG (1) | SG183117A1 (zh) |
| TW (1) | TWI422382B (zh) |
| WO (1) | WO2011106492A1 (zh) |
| ZA (1) | ZA201206068B (zh) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI459957B (zh) * | 2010-02-24 | 2014-11-11 | Colgate Palmolive Co | 口腔保健組成物 |
| SG190880A1 (en) | 2010-12-21 | 2013-07-31 | Colgate Palmolive Co | Halogenated biphenols as antibacterial agents |
| CN103764106B (zh) | 2011-09-08 | 2018-10-19 | 高露洁-棕榄公司 | 基于3,3’-二烷基-1,1’-联苯-2,2’-二酚或3,3’-二烯基-1,1’-联苯-2,2’-二酚的口腔和皮肤护理组合物 |
| JP2015500233A (ja) | 2011-12-02 | 2015-01-05 | コルゲート・パーモリブ・カンパニーＣｏｌｇａｔｅ−Ｐａｌｍｏｌｉｖｅ Ｃｏｍｐａｎｙ | オーラルケア組成物 |
| RU2014126871A (ru) * | 2011-12-02 | 2016-02-10 | Колгейт-Палмолив Компани | Композиции для гигиены полости рта |
| EP2790645B1 (en) | 2011-12-15 | 2016-10-05 | Colgate-Palmolive Company | Solubilized magnolol analogs |
| CA2857648A1 (en) * | 2011-12-15 | 2013-06-20 | Colgate-Palmolive Company | Oral care or cleanser composition comprising solubilized magnolol analogs and ppg-1- peg-9 lauryl glycol ether |
| CA2858032A1 (en) * | 2011-12-15 | 2013-06-20 | Colgate-Palmolive Company | Solubilized magnolol analogs |
| US9000231B2 (en) | 2011-12-20 | 2015-04-07 | Colgate-Palmolive Company | Processes for making magnolol and derivatives thereof |
| CN104066702B (zh) | 2011-12-20 | 2016-01-20 | 高露洁-棕榄公司 | 厚朴酚类似物的制备方法 |
| US9795548B2 (en) * | 2012-03-02 | 2017-10-24 | Colgate-Palmolive Company | Oral care compositions |
| WO2014115156A1 (en) | 2013-01-23 | 2014-07-31 | Colgate-Palmolive Company | Processes for making magnolol derivatives |
| WO2014131191A1 (en) * | 2013-03-01 | 2014-09-04 | Johnson & Johnson Consumer Companies, Inc. | A composition containing honokiol and/or magnolol and uses thereof |
| RU2744578C2 (ru) * | 2015-07-14 | 2021-03-11 | Вм. Ригли Джр. Компани | Экстракт коры магнолии в качестве гидрофобного лиганда для преимущественного удаления грамотрицательных бактерий из ротовой полости |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997035599A1 (en) * | 1996-03-26 | 1997-10-02 | Daewoong Pharmaceutical Co., Ltd. | Composition for prevention and treatment of periodontal diseases |
| WO2001082922A1 (en) * | 2000-04-27 | 2001-11-08 | The Procter & Gamble Company | Oral compositions comprising polyphenol herbal extracts |
| CN1331968A (zh) * | 2001-07-18 | 2002-01-23 | 广州美晨股份有限公司 | 一种中药牙膏 |
| WO2004000235A2 (en) * | 2002-06-25 | 2003-12-31 | Wm. Wrigley Jr. Company | Breath freshening and oral cleansing product with magnolia bark extract |
| CN101132806A (zh) * | 2004-12-29 | 2008-02-27 | 高露洁-棕榄公司 | 使用木兰提取物减少口腔组织炎症的方法 |
| CN101222909A (zh) * | 2005-07-14 | 2008-07-16 | Wm.雷格利Jr.公司 | 包括厚朴提取物和表面活性剂的口气清新和口腔清洁产品 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6500409B1 (en) | 2000-05-10 | 2002-12-31 | Colgate Palmolive Company | Synergistic antiplaque/antigingivitis oral composition |
| US6544409B2 (en) | 2001-05-16 | 2003-04-08 | Petroleo Brasileiro S.A. - Petrobras | Process for the catalytic oxidation of sulfur, nitrogen and unsaturated compounds from hydrocarbon streams |
| US7347985B2 (en) * | 2002-06-25 | 2008-03-25 | Wm. Wrigley Jr. Company | Breath freshening and oral cleansing product with magnolia bark extract |
| US20060127329A1 (en) * | 2004-12-10 | 2006-06-15 | Colgate-Palmolive Company | Tartar control oral care composition containing extract of magnolia |
| US8900644B2 (en) * | 2004-12-22 | 2014-12-02 | Colgate-Palmolive Company | Oral care compositions containing compounds from magnolia and hops extracts |
| US8071077B2 (en) * | 2004-12-29 | 2011-12-06 | Colgate-Palmolive Company | Oral compositions containing biphenol antibacterial compounds |
| US20060140885A1 (en) * | 2004-12-29 | 2006-06-29 | Abdul Gaffar | Method of reducing oral tissue inflammation using magnolia extract |
| WO2006129898A1 (en) | 2005-05-30 | 2006-12-07 | Korea Institute Of Oriental Medicine | A mass separation method of magnolol from magnoliae cortex ormagnoliae radix |
| WO2008006582A1 (en) * | 2006-07-14 | 2008-01-17 | Dsm Ip Assets B.V. | Compositions comprising magnolol or honokiol and other active agents for the treatment of inflammatory diseases |
| RU2440821C2 (ru) | 2007-10-01 | 2012-01-27 | Колгейт-Палмолив Компани | Композиции для ухода за полостью рта, содержащие растительные экстракты |
-
2011
- 2011-02-23 TW TW100105895A patent/TWI422382B/zh not_active IP Right Cessation
- 2011-02-24 SG SG2012055778A patent/SG183117A1/en unknown
- 2011-02-24 MX MX2012009139A patent/MX2012009139A/es active IP Right Grant
- 2011-02-24 BR BR112012019997A patent/BR112012019997A2/pt not_active IP Right Cessation
- 2011-02-24 RU RU2012140474/15A patent/RU2552322C2/ru not_active IP Right Cessation
- 2011-02-24 WO PCT/US2011/026017 patent/WO2011106492A1/en active Application Filing
- 2011-02-24 CN CN201180010909.XA patent/CN102762219B/zh not_active Expired - Fee Related
- 2011-02-24 JP JP2012555134A patent/JP5665888B2/ja not_active Expired - Fee Related
- 2011-02-24 AR ARP110100555A patent/AR080294A1/es unknown
- 2011-02-24 US US13/575,671 patent/US9801940B2/en active Active
- 2011-02-24 EP EP11706721.5A patent/EP2523676B1/en active Active
- 2011-02-24 RU RU2015114797/15A patent/RU2015114797A/ru not_active Application Discontinuation
- 2011-02-24 CA CA2788423A patent/CA2788423A1/en not_active Abandoned
- 2011-02-24 AU AU2011220789A patent/AU2011220789B2/en not_active Ceased
-
2012
- 2012-08-03 CO CO12131457A patent/CO6592076A2/es not_active Application Discontinuation
- 2012-08-13 ZA ZA2012/06068A patent/ZA201206068B/en unknown
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997035599A1 (en) * | 1996-03-26 | 1997-10-02 | Daewoong Pharmaceutical Co., Ltd. | Composition for prevention and treatment of periodontal diseases |
| WO2001082922A1 (en) * | 2000-04-27 | 2001-11-08 | The Procter & Gamble Company | Oral compositions comprising polyphenol herbal extracts |
| CN1331968A (zh) * | 2001-07-18 | 2002-01-23 | 广州美晨股份有限公司 | 一种中药牙膏 |
| WO2004000235A2 (en) * | 2002-06-25 | 2003-12-31 | Wm. Wrigley Jr. Company | Breath freshening and oral cleansing product with magnolia bark extract |
| CN101132806A (zh) * | 2004-12-29 | 2008-02-27 | 高露洁-棕榄公司 | 使用木兰提取物减少口腔组织炎症的方法 |
| CN101222909A (zh) * | 2005-07-14 | 2008-07-16 | Wm.雷格利Jr.公司 | 包括厚朴提取物和表面活性剂的口气清新和口腔清洁产品 |
Non-Patent Citations (4)
| Title |
|---|
| 于占洋；等: "中药预防龋齿研究的进展", 《国外医学.药学分册》, no. 6, 31 December 1986 (1986-12-31), pages 363 - 366 * |
| 徐连英、侯世祥主编: "《中药制药工艺技术解析》", 31 December 2003, 人民卫生出版社, article "中药溶液剂中如何使用潜溶剂？", pages: 523-524 * |
| 芦金清: "厚朴含漱液的研制与应用", 《中国医院药学杂志》, no. 10, 31 December 1993 (1993-12-31) * |
| 黄冰冰: "天然植物药防龋的研究进展", 《牙体牙髓牙周病学杂志》, vol. 12, no. 10, 31 December 2002 (2002-12-31), pages 574 - 576 * |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2552322C2 (ru) | 2015-06-10 |
| AR080294A1 (es) | 2012-03-28 |
| TWI422382B (zh) | 2014-01-11 |
| JP2013520517A (ja) | 2013-06-06 |
| EP2523676B1 (en) | 2016-04-20 |
| US20120294812A1 (en) | 2012-11-22 |
| JP5665888B2 (ja) | 2015-02-04 |
| US9801940B2 (en) | 2017-10-31 |
| RU2015114797A (ru) | 2015-09-20 |
| ZA201206068B (en) | 2015-04-29 |
| WO2011106492A1 (en) | 2011-09-01 |
| AU2011220789B2 (en) | 2013-07-18 |
| RU2012140474A (ru) | 2014-03-27 |
| EP2523676A1 (en) | 2012-11-21 |
| TW201204376A (en) | 2012-02-01 |
| CO6592076A2 (es) | 2013-01-02 |
| AU2011220789A1 (en) | 2012-08-23 |
| SG183117A1 (en) | 2012-09-27 |
| CA2788423A1 (en) | 2011-09-01 |
| CN102762219B (zh) | 2016-05-04 |
| MX2012009139A (es) | 2012-09-21 |
| BR112012019997A2 (pt) | 2019-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102762219B (zh) | 口腔护理组合物 | |
| CN103025305A (zh) | 包含木兰树皮提取物或其合成类似物的口腔护理组合物 | |
| CN101453900A (zh) | 啤酒花树脂的水溶性药物组合物 | |
| CN104066417B (zh) | 包含异丁基厚朴酚的口腔护理组合物 | |
| CN103957870B (zh) | 包含正丁基厚朴酚和异丁基厚朴酚的口腔护理组合物 | |
| JP2011246354A (ja) | 皮膚外用剤 | |
| JP2012006902A (ja) | 肌改善のための外用剤セット及びこれを使用する美容方法 | |
| CN102781439A (zh) | 口腔护理组合物和方法 | |
| CN104135992B (zh) | 口腔护理组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160504 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |